rezafungin acetate + co-trimoxazole

Rezafungin acetate is a next-generation, semi-synthetic echinocandin antifungal indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative options. It acts by inhibiting the fungal-specific enzyme 1,3-beta-D-glucan synthase, essential for fungal cell wall synthesis, leading to cell wall rupture and death. Rezafungin is notable for its long half-life (over 130 hours), allowing once-weekly intravenous dosing[3][5][6]. Co-trimoxazole is a fixed combination antibacterial agent containing trimethoprim and sulfamethoxazole. It inhibits sequential steps in bacterial folate synthesis, providing broad-spectrum activity against various bacteria and some protozoa. Co-trimoxazole is used to treat infections such as urinary tract infections, respiratory tract infections (including Pneumocystis jirovecii pneumonia), gastrointestinal infections, and others[1][4][7]. The combination of rezafungin acetate with co-trimoxazole has been studied in clinical trials for the treatment of Pneumocystis pneumonia (PCP) in HIV-infected adults[2].

Brand names

RezzayoBactrimSeptraSulfatrim

Other names

biafungintrimethoprim + sulfamethoxazole